SLC16A1 and glioma: Such mechanistic clarity will not only refine our understanding of metabolic–epigenetic–immune crosstalk but also support the rational development of therapies such as LDHA or MCT inhibition in combination with immunotherapy—particularly in lactate-high, immune-cold glioma subtypes.